RAD001H
Drug
Novartis Pharma AG
Total Payments
$21,367
Transactions
6
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $860.00 | 1 | 1 |
| 2017 | $20,507 | 5 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $12,595 | 4 | 58.9% |
| Travel and Lodging | $8,772 | 2 | 41.1% |
Payments by Type
Research
$12,595
4 transactions
General
$8,772
2 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CRAD001H2307 | Novartis Pharma AG | $12,595 | 1 |
Top Doctors Receiving Payments for RAD001H
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| John Fung | Transplant Surgery | Chicago, IL | $21,367 | 6 |
Ad
Manufacturing Companies
- Novartis Pharma AG $21,367
Product Information
- Type Drug
- Total Payments $21,367
- Total Doctors 1
- Transactions 6
About RAD001H
RAD001H is a drug associated with $21,367 in payments to 1 healthcare providers, recorded across 6 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharma AG.
Payment data is available from 2017 to 2018. In 2018, $860.00 was paid across 1 transactions to 1 doctors.
The most common payment nature for RAD001H is "Unspecified" ($12,595, 58.9% of total).
RAD001H is associated with 1 research study, including "CRAD001H2307" ($12,595).